CymaBay Therapeutics in the NEWS CymaBay Therapeutics (CBAY) today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC). Seladelpar is a first-in-class oral, selective PPARδ agonist being investigated for the treatment of patients with primary . . . This content is for paid subscribers. Please click here …
CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live Audio Website at 4.30 PM TODAY CymaBay Therapeutics, Inc. (CBAY) - a clinical-stage biopharmaceutical company developing therapies for liver and other chronic diseases with high unmet need, announced that it will host a conference call and live audio webcast Today, Thursday . . . This content is for paid …
Important News from CymaBay Therapeutics Primary Biliary Cholangitis Today, April 21, 2023, CymaBay Therapeutics (CBAY) announced that results from the ENHANCE phase 3 global study evaluating seladelpar for Primary Biliary Cholangitis (PBC) have been published in Hepatology. The authors . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
CymaBay Therapeutics CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical firm focused on improving the lives of people with liver and other chronic diseases that have a high unmet medical need through a pipeline of innovative therapies. The firm is proud of its deep understanding of the underlying mechanisms of liver inflammation . . . This content is for paid subscribers. Please click here to subscribe or …
Impacting News from Novavax, CymaBay Therapeutics and Sanofi SA Novavax The Grant That Rallied the Stock Novavax (NVAX) stock jumped sky-high following the announcement that the firm has been granted up to $384 million by the coalition for Epidemic Preparedness innovation. The grant is to help the advancement in the clinical development of the firm’s SARS-CoV-2 (COVID . . . This content is for paid …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
